Hikal Ltd. announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a loss of ₹75 million for the period, a notable decrease from the previous year. Revenue from operations stood at ₹3,998 million. The results also provide insights into segment-wise performance and comprehensive income.
Hikal Ltd. Reports Q1 FY27 Financial Performance
Hikal Limited has disclosed its unaudited standalone financial results for the first quarter of the financial year 2026-27, ending on June 30, 2026. The company announced a loss of ₹75 million for the quarter, compared to a profit in the previous year. This figure is detailed in the ‘Profit/(loss) for the period’ section.
Revenue and Expenses
Total revenue from operations for the quarter amounted to ₹4,028 million. Key expenses included Cost of materials consumed at ₹1,940 million and Other expenses totaling ₹1,100 million. The company reported a Profit/(loss) before tax before exceptional item of ₹(189) million, and after exceptional items, the Profit/(loss) before tax after exceptional item was ₹(100) million.
Comprehensive Income and Earnings Per Share
Other comprehensive income for the period was ₹2 million. Consequently, the Total comprehensive income/(loss) for the quarter stood at ₹(73) million. Earnings per share (EPS) for the quarter were Basic: ₹(0.61) and Diluted: ₹(0.61).
Segment Performance Highlights
The standalone segment-wise analysis reveals that the Pharmaceuticals segment reported a profit before tax of ₹15 million, while the Crop protection segment incurred a loss before tax of ₹(89) million. Segment assets were primarily driven by the Pharmaceuticals segment at ₹14,402 million, and segment liabilities were dominated by unallocable items at ₹7,758 million.
Source: BSE
